Protective effect of a direct renin inhibitor in acute murine model of cardiotoxicity and nephrotoxicity

Fundamental and Clinical Pharmacology

Volumn 28, Issue 5, 2014, Pages 489-500

  Rashikh, Azhar ^a   Pillai, Krishna Kolappa ^a   Najmi, Abul Kalam ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Aliskiren; Cardiomyopathy; Doxorubicin; Lipid peroxidation; Nephropathy; Renin angiotensin aldosterone system

Indexed keywords

ALBUMIN; ALISKIREN; ANGIOTENSIN I; CASPASE 3; CREATININE; DOXORUBICIN; GLUTATHIONE; LACTATE DEHYDROGENASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TELMISARTAN; UREA; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE; RENIN;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; HEART PROTECTION; HEART WEIGHT; KIDNEY DISEASE; KIDNEY MASS; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID PEROXIDATION; MEAN ARTERIAL PRESSURE; NEPHROTOXICITY; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; TRANSMISSION ELECTRON MICROSCOPY; UREA BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; ENZYMOLOGY; HEART MUSCLE; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY DISEASES; ORAL DRUG ADMINISTRATION; WISTAR RAT;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOTOXICITY; DISEASE MODELS, ANIMAL; DOXORUBICIN; FUMARATES; INJECTIONS, INTRAPERITONEAL; KIDNEY DISEASES; MYOCARDIUM; RATS; RATS, WISTAR; RENIN;

EID: 84927581612     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12054     Document Type: Article

References (64)

1. Escherich G., Zimmermann M., Janka-Schaub G. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. Pediatr. Blood Cancer (2013) 60 254-257.
2. Perez E.A., Suman V.J., Davidson N.E., Sledge G.W., Kaufman P.A., Hudis C.A. Analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J. Clin. Oncol. (2008) 26 1231-1238.
3. Octavia Y., Tocchetti C.G., Gabrielson K.L., Janssens S., Crijns H.J., Moens A.L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. (2012) 52 1213-1225.
4. Lahoti T., Patel D., Thekkemadom V., Beckett R., Ray S.D. Doxorubicin-induced in vivo Nephrotoxicity involves oxidative stress-mediated multiple pro- and anti-apoptotic signaling pathways. Curr. Neurovasc. Res. (2012) 9 282-295.
5. Nazmi A.S., Ahmad S.J., Rashikh A., Akhtar M., Pillai K.K., Najmi A.K. Protective effects of 'Khamira Abresham Hakim Arshad Wala', a unani formulation against doxorubicin-induced cardiotoxicity and nephrotoxicity. Toxicol. Mech. Methods (2011) 21 41-47.
6. Davies K.J., Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. (1986) 261 3060-3067.
7. Fu Z., Guo J., Jing L., Li R., Zhang T., Peng S. Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice. Toxicology (2010) 24 1584-1591.
8. Shi J., Zhang L., Zhang Y.W., Surma M., Payne R.M., Wei L. Down-regulation of doxorubicin-induced myocardial apoptosis accompanies postnatal heart maturation. Am. J. Physiol. Heart Circ. Physiol. (2012) 302 H1603-H1613.
9. Wallace K.B. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc. Toxicol. (2007) 7 101-107.
10. Aluise C.D., Miriyala S., Noel T. et al. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-α release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic. Biol. Med. (2011) 50 1630-1638.
11. Jing L., Zhang J., Sun J. et al. Inhibition of extracellular signal-regulated kinases ameliorates hypertension-induced renal vascular remodeling in rat models. Int. J. Mol. Sci. (2011) 12 8333-8346.
12. Vapa I., Torres V.M., Djordjevic A. et al. Effect of fullerenol C(60)(OH) (24) on lipid peroxidation of kidneys, testes and lungs in rats treated with doxorubicine. Eur. J. Drug Metab. Pharmacokinet. (2012) 37 301-307.
13. Berthiaume J.M., Oliveira P.J., Fariss M.W., Wallace K.B. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc. Toxicol. (2005) 5 257-267.
14. El-Shitany N.A., El-Haggar S., El-desoky K. Silymarin prevents adriamycin induced cardiotoxicity and nephrotoxicity in rats. Food Chem. Toxicol. (2008) 46 2422-2428.
15. Lebrecht D., Geist A., Ketelsen U.P. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br. J. Pharmacol. (2007) 151 771-778.
16. Sacco G., Bigioni M., Evangelista S., Goso C., Manzini S., Maggi C.A. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur. J. Pharmacol. (2001) 414 71-78.
17. Soga M., Kamal F.A., Watanabe K. et al. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int. J. Cardiol. (2006) 110 378-385.
18. Iqbal M., Dubey K., Anwer T., Agrawal A., Pillai K.K. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol. Rep. (2008) 60 382-390.
19. Hollenberg N.K., Fisher N.D., Price D.A. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension (1998) 32 387-392.
20. Ichihara S., Senboumatsu T., Price E.J. Angiotensin II type 2 receptor is essential for left ventricular fibrosis in chronic angiotensin II-induced hypertension. Circulation (2001) 104 346-351.
21. Toko H., Oka T., Zou Y. et al. Angiotensin II type Ia receptor mediates doxorubicin-induced cardiomyopathy. Hypertens. Res. (2002) 25 597-603.
22. Gradman A.H., Kad R. Renin inhibition in hypertension. J. Am. Coll. Cardiol. (2008) 51 519-528.
23. Gradman A.H., Schmieder R.E., Robert L. et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 111 1012-1018.
24. Porstmann T., Kiessig S.T. Enzyme immunoassay techniques, an overview. J. Immunol. Meth. (1992) 150 5-21.
25. Lum G., Gambino S.R. A comparison of serum Vs heparinised plasma for routine chemistry tests. Am. J. Clin. Pathol. (1974) 61 108-113.
26. Young D.S. Effects of drugs on clinical laboratory tests. Ann. Clin. Biochem. (1997) 34 579-581.
27. Koller A. Proteins in clinical chemistry: theory, analysis and correlation. CV. Mosby, Toronto, 1984, pp. 1268-1327.
28. Wang J.J. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy; Evidence for Antifibrogenic Activities. Diabetes (2006) 55 1678-1685.
29. Fawcett J.K., Scott J.E. A rapid and precise method for the determination of urea. J. Clin. Pathol. (1960) 13 156-159.
30. Sharma H., Pathan R.A., Kumar V., Javed S., Bhandari U. Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy. Int. J. Cardiol. (2011) 150 193-200.
31. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. (1970) 34 30-38.
32. Sedlack J., Lindsay R.H. Estimation of total, protein bound and non-protein bound sulfhydryl groups in tissue with Ellman's reagent. Anal. Biochem. (1968) 25 192-205.
33. Marklund S., Marklund G. Involvement of superoxide anion radical in auto-oxidation by pyrogallol and a convenient assay of superoxide dismutase. Eur. J. Biochem. (1974) 47 469-474.
34. Lowry O.H., Rosebrough N.H., Farr A.L., Randall R.J. Protein measurements with the Folin Phenol Reagent. J. Biol. Chem. (1951) 193 265-275.
35. Pathan R.A., Singh B.K., Pillai K.K. Naproxen aggravates Doxorubicin-induced cardiomyopathy in rats. Indian J. Pharmacol. (2010) 42 44-49.
36. Mifsud S.A., Allen T.J., Bertram J.F. et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia (2001) 44 878-882.
37. Whaley-Connell A.T., Chowdhury N.A., Hayden M.R. et al. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am. J. Physiol. Renal Physiol. (2006) 291 F1308-F1314.
38. Yilmaz S., Atessahin A., Sahna E., Karahan I., Ozer S. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology (2006) 218 164-171.
39. Doroshow J.H., Davies K.J. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem. (1986) 261 3068-3074.
40. Mimnaugh E.G., Trush M.A., Gram T.E. A possible role of membrane lipid peroxidation in anthracycline nephrotoxicity. Biochem. Pharmacol. (1986) 35 4327-4335.
41. Xu M.F., Tang P.L., Qian Z.M., Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. (2001) 68 889-901.
42. Saraogi P., Pillai K.K., Singh B.K., Dubey K. Rosiglitazone and pioglitazone aggravate doxorubicin-induced cardiomyopathy in wistar rats. Biomed. Pharmacother. (2011) 1 65-71.
43. Khan M., Shobha J.C., Mohan I.K. et al. Protective effect of spirulina against doxorubicin-induced cardiotoxicity. Phytother. Res. (2005) 19 1030-1037.
44. Zou M.S., Yu J., Nie G.M., He W.S., Luo L.M., Xu H.T. 1, 25-dihydroxyvitamin D3 decreases adriamycin-induced podocyte apoptosis and loss. Int. J. Med. Sci. (2010) 7 290-299.
45. Herman E.H., Ferrans V.J. Animal models of anthracycline cardiotoxicity: basic mechanisms and cardioprotective activity. Prog Pediatr Cardiol. (1998) 8 49-58.
46. Rossi F., Filippelli W., Russo S., Filippelli A., Berrino L. Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharmacol. Toxicol. (1994) 75 99-107.
47. Tokudome T., Mizushige K., Noma T. et al. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J. Cardiovasc. Pharmacol. (2000) 36 361-368.
48. Flad T.M., Conway J.D., Cunningham S.K., McKenna T.J. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency. Clin. Endocrinol. (1996) 45 529-534.
49. Zupan I., Krhin B., Breskvar U.P., Zupan I., Rakovec P. Effects of systolic atrial function on plasma renin activity and natriuretic peptide secretion after high rate atrial and ventricular pacing in dogs. Pacing Clin. Electrophysiol. (2005) 1 S270-S274.
50. Arnolda L., Mcgrath B., Cocks M., Sumithran E., Johnston C. Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms. Cardiovasc. Res. (1985) 19 378-382.
51. Bocherens-Gadient S.A., Quast U., Nussberger J., Brunner H.R. Chronic adriamycin treatment and its effect on the cardiac beta-adrenergic system in the rabbit. J. Cardiovasc. Pharmacol. (1992) 19 770-778.
52. Smithies O. A mouse view of hypertension. Hypertension (1997) 30 1318-1324.
53. Nakamura T., Ueda Y., Juan Y., Katsuda S., Takahashi H., Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation (2000) 102 572-578.
54. Zhu W., Zou Y., Aikawa R. et al. MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation (1999) 100 2100-2107.
55. Singh B.K., Pathan R.A., Pillai K.K., Haque S.E., Dubey K. Diclofenac sodium, a nonselective nonsteroidal anti-Inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats. J. Cardiovasc. Pharmacol. (2010) 55 139-144.
56. Bulucu F., Oktenli C., Kenar L. et al. Efficacy of deferoxamine, N-acetylcysteine and selenium treatments in rats with Adriamycin-induced nephrotic syndrome. J. Nephrol. (2008) 21 576-583.
57. Mansouru M., El-kashef H., Al-shabanah O. Effect of captopril on doxorubicin-induced nephrotoxicity in normal rats. Pharmacol. Res. (1999) 39 239-245.
58. Venkatesan N., Punithavathi D., Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. Br. J. Pharmacol. (2000) 129 231-234.
59. Wang X.Y., Yang C.T., Zheng D.D. et al. Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress. Mol. Cell. Biochem. (2012) 363 419-426.
60. Ludke A., Sharma A.K., Bagchi A.K., Singal P.K. Subcellular basis of vitamin C protection against doxorubicin-induced changes in rat cardiomyocytes. Mol. Cell. Biochem. (2012) 360 215-224.
61. Somlo S., Mundel P. Getting a foothold in nephrotic syndrome. Nat. Genet. (2000) 24 333-335.
62. Mori K., Mukoyama M., Nakao K. PPAR-α transcriptional activity is required to combat doxorubicin-induced podocyte injury in mice. Kidney Int. (2011) 79 1274-1276.
63. He L., Rong X., Jiang J.M., Liu P.Q., Li Y. Amelioration of anti-cancer agent adriamycin-induced nephrotic syndrome in rats by Wulingsan (Gorei-San), a blended traditional Chinese herbal medicine. Food Chem. Toxicol. (2008) 46 1452-1460.
64. Zhu C., Huang S., Ding G. et al. Protective effects of Huang Qi Huai granules on adriamycin nephrosis in rats. Pediatr. Nephrol. (2011) 26 905-913.